Morning, John R Fischer here with the US Wire from the New York newsroom.
AI and regulatory complexity are driving demand for life sciences software. This has attracted private equity, with firms such as Ardian, Bregal Sagemount, Eir Partners and Thoma Bravo transacting in the segment. We’ll discuss these tailwinds and a few of these investments in my eight-deal listicle.
Sticking with our life sciences theme for Friday Focus. This time the spotlight is on the manufacturing subsegment, where 1315 Capital has closed a carve-out deal with a portfolio company of Telegraph Hill Partners and New Vale Capital.
Software surge
Life sciences are experiencing an accelerating pace of breakthroughs that “we only expect to continue with the application of AI across pharmaceutical research and regulatory workflows,” Harrison Brunelli, principal at Bregal Sagemount, told PE Hub.
“We believe this creates a significant opportunity for investment in the next generation of technology that enables life sciences companies to implement agentic AI systems and modern data architecture to scale development and commercialization efforts.”
In an increasingly complex regulatory environment, software businesses helping pharmaceutical companies and contract research organizations with data traceability and compliance are particularly sought after by private equity.
I rounded up eight deals in life sciences software dating back to March. Here are three:
Eir Partners announced in September the acquisition of Accumulus Technologies, a platform that enables life sciences organizations and regulatory authorities to collaborate and exchange information in a secure, cloud-based environment.
Operating out of San Francisco, Accumulus was spun out in 2025 by nonprofit Accumulus Synergy as a standalone commercial organization to raise capital, form partnerships and scale its platform. It has more than 75 regulatory authorities connected today.
Eir Partners plans to increase investments in the company’s technology and capabilities; support continued global adoption of its software; and expand its reach across the regulatory ecosystem.
“Its purpose-built platform, engagement across industry and regulatory authorities and potential to transform how life sciences companies and regulatory authorities interact make Accumulus a compelling partnership for Eir,” said Brett Carlson, founder and CEO of Eir Partners, in a statement.
In August, Thoma Bravo announced the completed take-private of Kneat Solutions in an all-cash transaction of $466 million (€404 million; C$650 million).
The purchase price of C$6.50 per share represents a premium of approximately 40 percent to Kneat’s closing price on May 8, the last trading day before the Limerick, Ireland-based company announced a strategic review. It also represents a premium of approximately 20 percent to the closing price on June 5, the last trading day prior to Thoma Bravo’s announcement of its intent to acquire the company.
With the company’s software platform, Kneat Gx, life sciences companies can digitalize data for integrity and traceability in validation and compliance processes for pharma, biotech and medical devices, equipment and systems. The software includes AI for accelerating validation, and the company also offers auditing services for compliance and documentation.
“Kneat has established itself as a vital platform for life sciences and highly regulated enterprises and is well positioned to capitalize on growing market demand and increasing validation complexity,” said Chandler Gay, senior vice president at Thoma Bravo, in a statement.
In July, Bregal Sagemount and Ardian closed an investment in Ennov, a clinical software provider for life sciences and healthcare companies. The two PE firms previously announced an agreement to invest in May.
Ennov is based in Paris and provides software for regulated content, data and process management. It supports the entire life sciences R&D continuum including clinical, regulatory, quality, pharmacovigilance and commercial requirements.
The investment is expected to support Ennov’s continued expansion, with a focus on AI innovation, global go-to-market acceleration and scaling its product offering.
“Pharmaceutical companies are managing increasingly complex regulatory requirements as they bring new products to market across jurisdictions with different regimes,” said Brunelli. “These workflows are mission-critical and resilient through economic cycles. Further, speed to market is directly impacted by the speed and accuracy of regulatory processes. Bregal Sagemount canvassed the sector around this thesis and built a relationship with Ennov over several years before the opportunity to invest emerged.”
Beyond the completed deals in our listicle, more are coming. In July, Nordic Capital agreed to sell ArisGlobal, a provider of regulatory, safety and quality software for the life sciences industry, to Dassault Systèmes, a French multinational software corporation. The deal is a full exit for Nordic Capital, which acquired ArisGlobal in 2019 for nearly $800 million and made a further investment in 2021. The transaction is expected to close in the second half of 2026.
Friday Focus
Carve-out focused investors are well positioned to identify strong businesses, particularly those that have been under-prioritized within a larger corporate, but which have “defensible market positions, strong fundamentals and clear growth potential,” Christoph Leitner-Dietmaier, partner, at Montagu told PE Hub in July.
“These businesses often need the focus, investment and operational support that comes with becoming an independent platform,” he added. “The transaction itself may be complex, but for the right investor, the value creation thesis is very clear.”
Earlier this week, we saw another firm bet on the value creation opportunity a carve-out can provide. 1315 Capital announced a carve-out of the life sciences and diagnostics division (LSDx) of Argonaut Manufacturing Services, a contract development and manufacturing organization backed by Telegraph Hill Partners, New Vale Capital and management.
Based in Carlsbad, California, Argonaut specializes in aseptic fill-finish – the packaging of pharmaceutical products – of high-value injectable biologics and pharmaceuticals.
Under 1315 Capital, the LSDx division will operate independently as Aluris Sciences. It will continue to provide manufacturing services across formulation, filling, kitting, lyophilization, assembly, packaging and supply chain management that support customers from pilot-stage programs through clinical, validation and commercial production.
“The two businesses already operated with largely separate staff and resources, allowing the transition to occur without disrupting any existing customer programs,” said Rick Hancock, chief executive officer of Argonaut, in a statement. “Argonaut will reinvest the proceeds from the sale in its core operations, including expanding its fill-finish capacity and services.”
Well, that’s it for me. Nina Lindholm will be back in the Europe chair on Monday, and Rafael Canton will have the US Wire for you then as well. Before I sign off, on behalf of everyone at PE Hub, we remember those whose lives were lost on this day 25 years ago.
John